Objective To study the effectiveness of intrahepatic arterial infusion of recombinant human endostatin combined with transcatheter arterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Methods 20 cases in study group received intrahepatic arterial infusion of recombinant human endostatin together with TACE, while 20 patients of control group received TACE only. Within one year after the treatment, color ultrasonic was re-examined per two months. The contral condition of the tumor and the formation of tumor angiogenesis were surveyed and assessed. Moreover, one-year survival rates were observed between two groups. Results The one-year survival rate of study group was significantly higher than that of control group, with P =0. 035. The inhabitation rate of tumor angiogenesis in study group was markedly higher than the inhabitation rate of control group, with P =0. 025, Also, disease control rate of study group was higher than that of control group, with P =0. 038. Conclusion Intrahepatic arterial infusion of recombinant human endostatin combined with TACE can significantly increase the one-year survival rate, it can also inhibit both the formation of tumor angiogenesis and the occurrence of metastasis. This treatment is really worth being further applied.%目的 研究肝动脉化疗栓塞联合血管内皮抑素治疗肝癌的临床疗效.方法 治疗组20例为TACE联合重组人内皮抑素经动脉灌注,对照组20例为单纯TACE,所有患者术后1年内每2月复查彩超检查,观察肿瘤控制情况、新生血管抑制情况,并观察1年内生存率.结果 治疗组1年生存率高于对照组(P =0.035),治疗组肿瘤新生血管抑制率明显高于对照组(P =0.025),治疗组疾病控制率(DCR)显著高于对照组(P=0.038).结论 内皮抑索联合TACE治疗肝癌,患者1年生存率显著提高,肿瘤新生血管、转移抑制明显,值得临床推广.
展开▼
